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Section 1: HIV-1 Multidrug Resistant Protease with Residue 28 Insertion
CHAPTER I: INTRODUCTION
1.1 HIV-1 Viral Background
Human immunodeficiency virus (HIV) is a positive-sense, enveloped lentivirus that infects
CD4+ T cells and can lead to the development of acquired immune deficiency syndrome (AIDS)
[2].
1.2 Clinical Background
The Center for Disease Control (CDC) estimates that 1.2 million people are living with HIV in
the United States as of 2013 and about 36.7 million people worldwide as of June 2016 (CDC,
2016). HIV remains a worldwide concern as fatalities due to opportunistic infections continue to
occur [3]. HIV is a retrovirus predominantly found as the HIV-1 strain [4, 5] . HIV-1 contains
different viral proteins necessary for propagating its viral life cycle, one of which is the HIV-1
protease [6-9] .
1.3 Viral Mechanism/Protease Significance
HIV-1 protease (HIV-1 PR) is a 99 amino acid aspartyl protease that cleaves the Gag and Gagpol polyproteins in 9 locations to release mature proteins required for new virion assembly [6, 7,
10-12]. The mechanism underlying the cleavage of the polyproteins is an almost symmetric
interaction between the substrate and the catalytic aspartate residues from each monomer [13,
14].
1.4 Mutations/Insertions
Inhibiting the HIV-1 PR with one of nine FDA-approved protease inhibitors (PI) has proven to
be a successful strategy to prevent viral maturation; however, drug resistance mutations in HIV-1
PR may act as a survival mechanism for the virus under pharmacologic pressure [15]. Multidrug
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resistant mutations acquired by HIV-1 PR render conventional protease treatments less effective
[12, 15-20], thus increasing the survival of the virus [12].
Insertion mutations are vastly underrepresented in the literature and their role remains unclear.
We have recently identified a clinical isolate from the Wayne State University Infectious Disease
Clinic in Detroit, MI which contains a five residue insertion between codons 28 and 29 of
multidrug resistant HIV-1 protease.
1.5 Specific Aim
To study the effects of the five residue insertion on HIV-1 PR function, we created a homology
model of the insertion mutant and submitted the model to a 40 ns molecular dynamics
simulation.
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CHAPTER II: MATERIAL AND METHODS
2.1 Phenotypic and Genotypic data
Phenotypic data for MDR28 was obtained by Phenosense® HIV drug resistance assay as
performed at the Detroit Medical Center [21]. Genotypic data from the sequence of the mutant
PR was provided by the Viroseq® HIV-1 genotyping system [22].
2.2 Homology Modeling
A homology model of multidrug resistant HIV-1 PR (MDR) containing a five amino acid
insertion, Asp-Asp-Thr-Ile-Leu (DDTIL), immediately to the c-terminal side of the 28th residue
(MDR28) was created using SWISS-MODEL [23-26]. A wild-type (WT) HIV-1 PR crystal
structure, 2O4S.pdb was obtained from the RCSB protein data bank and used as a template for
the MDR28 homology model [27]. A homology model for MDR without the insertion was made
using the same template (2O4S.pdb). The crystal structure 2O4S was used as a WT control. The
resulting homology model for the MDR28 was a homodimer containing a total of 208 amino
acids. The WT and MDR models each contained 198 amino acids. All of the models were
subjected to 40ns molecular dynamics(MD) simulations.
2.3 Molecular Dynamics Simulations
2.3.1 Protease Complex Preparation
Visual Molecular Dynamics (VMD) software (VMD v.1.9.2) [27] was used to prepare the
systems for MD simulations. WT, MDR, and MDR28 were prepared without a peptide (apo)
resulting in three systems, respectively.
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2.3.2 System Preparation
The preparation of the system for the MD simulation was carried out using VMD software
(VMD v.1.9.2) [28]. The PR complexes as well as the apo structures were placed in a 12 Å
TIP3P water box and were then neutralized with 0.15 M MgCl2. The simulations were performed
for 40ns using NAMD (e) V 2.9. [29] and CHARMM force field 36 to set parameters [30] as
previously described [31]. All simulations were run on the Wayne State University Grid
(www.grid.wayne.edu).
2.4 Analysis
2.4.1 Structural Analysis
All structural analysis was carried out using VMD (VMD v1.9.2) [28]. Frame 17,000 was
selected as a model frame for WT, MDR, and MDR28 out of the 20,000 frame simulation. This
frame was chosen as it is located further into the simulation after the proteases have had time to
adjust and stabilize.
RMSD values were calculated over the last 10 ns of the simulation using VMD (v 1.9.2).
RMSF values were calculated for all 40 ns of the simulation. Secondary structural analysis was
completed using the Ramachandran plot analysis tool. Ramachandran plots were used to analyze
residues 23-42 of all three protease models for the last 10 ns of the simulation. RMSD model
alignments of the full length PR, the hinge region, and the flap region were taken at 5 ns intervals
of each PR RMSD. Model averages of MDR and MDR28 aligned with WT were also taken at 5
ns intervals throughout the simulation using the RMSD alignment tool in the PyMOL Molecular
Graphics System (Version 1.8 Schrödinger, LLC).

5

CHAPTER III: RESULTS
3.1 Reduced replicative capacity and drug resistance of MDR28
In a Phenosense® susceptibility test, clinical isolate MDR28 displayed full or partial
resistance to the following protease inhibitors (PIs): atazanavir (ATV/r), amprenavir (AMP/r),
indinavir
(IDV/r),
tipranavir
(TRV), and

Table 1. Phenotypic and genotypic susceptibility data. Summary of phenotypic and genotypic resistance
data provided by Phenosense® and Viroseq®.

nelfinavir (NFV)
(Table 1).
Viroseq®, a
genotypic
antiretroviral drug
resistance report
was then
performed, and
MDR28 showed
resistance
mutations
impacting the PIs IDV, LPV,

Table 2. MDR28 resistance mutations and corresponding PI resistance.
Summary of Viroseq® HIV-1 genotype report with possible PI resistance
profile.

fosamprenavir (FPV), and
possible resistance to TPV, DRV, and ATV. Saquinavir (SQV) was the only inhibitor for which
there were no known resistance mutations present (Table 1). A list of resistance mutations found
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in MDR28, and their contributions
are available in Tables 1 and 2.
Genotypic reports are more
predictive of future drug resistance,
and the phenotypic data can be
predictive of the clinical outcome. It
was also determined in a
Phenosense® replicative capacity assay

Figure 1. Replicative Capacity. Comparison of replicative
capacity as percentage, visualized as a bar graph. MDR28
represented with green, WT represented with blue.

that in the absence
of inhibitors the
isolate MDR28
functioned at a
reduced replicative
capacity compared
to WT (only 29% of
WT) (Figure 1).

Figure 2. Sequence alignment MDR28, WT, and MDR. The
absence of an insertion is indicated by dashes (-), homology
indicated with by the presence of an asterisk (*), mutations
denoted by a colon (:).

3.2 Homology modeling of MDR28, WT, and MDR of MDR28, WT, and MDR:
Wildtype (WT) HIV-1 PR is a 99 amino acid aspartyl-protease. Two 99 amino acid
monomers form a homodimer to create active HIV-1 PR. [7, 8, 11, 12]. In dimer form, both WT
and multidrug resistant HIV-1 PR (MDR) contain 198 amino acids. MDR and the corresponding
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(b)

(a)

(c)

Figure 3. Ribbon representations of HIV-1 PR structures. (a) WT shown in magenta, catalytic
asp25 in red (b) MDR28 shown in in green, multi-drug mutations in orange, asp25 in red, and
insertion residues in yellow. (c) MDR shown in cyan with multidrug resistant mutations in
orange and asp25 in red

homology model showed 6 mutations within each monomer sequence. These mutations are
consistent in both MDR and our multidrug resistant HIV-1 PR (MDR28) isolate with an insertion
immediately following the carboxyl terminus of amino acid 28. This added insertion results in a
homodimer with 208 amino acids. (Figure 1)
The 5 residue insertion in MDR28 appears to promote the formation of an alpha helix in
the hinge region that is not present in WT or MDR (Figure 2).The hinge region of the proteases
are composed of amino acids 34-42 [2] , which normally affect the flap region and subsequent
conformational ability [2]. The flap region is composed of residues 43-59 [2] and is responsible
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for the proteases ability to take on an “open” or “closed” conformation, affecting its ability to
bind to the substrate [11].
3.3 Secondary structure analysis
To determine whether the alpha helix in MDR28 was transient or present throughout the VMD
simulation (VMD v.1.9.2) [28], the hinge regions of each model were analyzed with
Ramachandran diagrams. Ramachandran diagrams plot phi vs. psi angles of the peptide linkages
between amino acids, which compose the protease backbone [32]. Each data point represents one
of 5,000 frames that were analyzed (materials and methods). Plots were generated of the
insertion and the surrounding residues for each monomer (denoted as monomer A and monomer
B) over the last 10 ns of the simulation. The MDR28 insertion residues were labeled 28a-28e
(Figure 5). A change in secondary structure for MDR28 is consistent throughout the last 10ns of
the simulation. Alpha helix formation is observed at residues 29-35 in MDR28, corresponding to
residues 34-40 in WT and MDR (Figure 6). No comparable secondary structure changes were
seen in WT or MDR. No additional deviations in secondary structure were seen in surrounding
residues. (Figure 4, Figure 7).
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3.3.1 Prior to insertion
Chain P
23

24

25

26

27

28

23

24

25

26

27

28

MDR 28

MDR

WT

Chain P’

MDR 28

MDR

WT

Figure 4. Ramachandran plots prior to insertion. MDR28, MDR, and WT
residues 23-28 shown above. No obvious structural deviations noted.
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3.3.2 Insertion residues
Chain P
29/28a

30/28b

31/28c

32/28d

33/28e

29/28a

30/28b

31/28c

32/28d

33/28e

MDR 28

MDR

WT
Chain P’

MDR 28

MDR

WT

Figure 5. Ramachandran plots corresponding to insertion
residues. MDR and WT residues 29-33, and MDR28 residues 28a28e shown above. No obvious structural differences noted.
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3.3.3 After insertion

Chain P

Monomer A
34/29

35/30

36/31

37/32

38/33

39/34

40/35

34/29

35/30

36/31

37/32

38/33

39/34

40/35

MDR 28

MDR

WT
Chain P’

Monomer B

MDR 28

MDR

WT

Figure 6. Ramachandran plots after insertion. WT and MDR residues 34-40,
and MDR28 residues 29-35 shown above. Alpha helix formation observed in
residues 31-35 of MDR28 only.
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Chain P
41/36

42/37

43/38

44/39

45/40

46/41

41/36

42/37

43/38

44/39

45/40

46/41

47/42

MDR 28

MDR

WT
Chain P

MDR 28

MDR

WT

Figure 7. Ramachandran plots after insertion. MDR28, MDR, and WT
residues following insertion. No obvious structural changes observed

47/42
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3.4 Flexibility analysis through RMSF calculations
To determine if the addition of an alpha helix affected hinge and flap flexibility, RMSF was
analyzed across the 40 ns simulation. The RMSF calculations were analyzed with VMD software
(VMD v.1.9.2) [28]. Averages of the monomers of all three proteases— WT, MDR, and MDR28
were visualized as graphs (Figure 8) and models (Figure 9). No obvious changes in flexibility
were noted. RMSF values were visualized for the hinge (Figure 10) and flap residues (Figure
11) to ensure no changes were seen. The RMSF analysis did not show substantial changes in
flexibility between the proteases in any location.
3.4.1 RMSF averages of monomers

(a)

(b)

Figure 8. RMSF Averages of monomers. a) RMSF Averages represented as line graph with
average RMSF vs residue. b) RMSF averages for all residues represented by bar graph
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3.4.2 RMSF flexibility models
(b)

(a)

(c)

Figure 9. RMSF Represented by Model
Highlighting. Red indicates a high degree
of flexibility, blue indicates low degree of
flexibility. a) WT b) MDR c) MDR28

3.4.3 RMSF averages hinge region
(a)

(b)

Figure 10. RMSF Averages Hinge Residues. a) RMSF hinge residues
represented by RMSF vs Residue line graph b) RMSF hinge residues
visualized as bar graph
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3.4.4 RMSF flap region

(b)

(a)
(a)

Figure 11. RMSF Averages Flap Residues. a) RMSF flap residues
graphed as RMSF vs residue. b) RMSF flap residues visualized as a bar
graph

3.5 RMSD analysis
Due to the presence of an alpha helix throughout the 40 ns simulation in MDR28, the
effect of this structure on the flap and hinge dynamics were examined. RMSD analysis was
calculated using VMD (VMD V.1.9.2.) [25] to determine whether the alpha helix altered the
atomic coordinates in MDR28 compared to WT and MDR structures. Averaged RMSD values of
each protease were taken and represented as line and bar graphs (Figure 12). In the hinge region,
a peak is present at residue 39 of MDR28 (Figure 13). This deviation is not observed in WT or
MDR. The flap residues were visualized using the same graphing methods (Figure 14).
Comparatively, the dynamics of the flap region appear altered as well.
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3.5.1 RMSD averages homodimers and monomers
(a)

(b)

Figure 12. RMSD Averaged Monomer Values. a) Averaged monomer
values represented as line graph (RMSD vs residue). b) Averaged residues
visualized by bar graph

3.5.2 RMSD hinge region
(a)

(b)

Figure 13. Average hinge region RMSD values. a) RMSD hinge averages for WT
(blue), MDR (red), and MDR28 (green) represented by line graph (RMSD vs
residue b) Averaged hinge region RMSD represented by bar graph
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3.5.3 RMSD flap region
(a)

(b)

Figure 14. Average flap region RMSD values. a) RMSD flap region averages
for WT (blue), MDR (red), and MDR28 (Green) represented by line graph
(RMSD vs residue). b) Averaged flap region RMSD represented by bar graph

3.6 RMSD model analysis at 5 ns intervals suggests increased structural similarity:
To determine whether the dynamics information translated to similarities in structural
alignment, RMSD values of MDR and MDR28 aligned with WT were taken at 5 ns intervals
throughout the simulation. The model alignment values were measured using the RMSD
alignment tool in the PyMOL Molecular Graphics System (Version 1.8 Schrödinger, LLC). The
results suggest that over time MDR28 acts with increased structural similarity to WT. MDR28
consistently showed higher average similarity to WT in all three datasets—full length PR
(Figure 15), hinge region (Figure 16), and flap region (Figure 17). The data for MDR and
MDR28 were visualized using line graphs representing RMSD compared to WT vs time. Data
averages for each region were visualized using bar graphs. The largest deviation in structural
similarity between MDR and MDR28 when compared to WT, was seen between the flap regions
(Figure 17), where MDR28 continued to show the highest amount of similarity to WT. The flap
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region is imperative in accessibility to the active site, and subsequent substrate recognition and
cleavage [33]. Furthermore, in previous studies mutant isolates were compared and those
differing in only the insertions showed higher overall rates of replication [14]. MDR28 appears
to compensate for MDR mutations by increasing structural similarity to WT. These results may
indicate compensation to promote viral fitness as the underlying mechanism that promotes
cleavage of the polyproteins. Subsequently, this would be dependent on proper structure and
subsequent interactions between the substrate and the catalytic residue asp25 [13, 14].
3.6.1 RMSD full length model analysis:
(a)

(b)

Figure 15. RMSD Model Alignment. a) RMSD PR alignments at 5 ns intervals
visualized by line graph (RMSD compared to WT vs Time). b) RMSD Alignment
PR averages visualized as bar graph.
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3.6.2 RMSD hinge region model analysis:
(b)

(a)

Figure 16. RMSD Model Alignment Hinge Region. a) RMSD hinge region
alignments at 5 ns intervals visualized by line graph (RMSD compared to WT vs
Time). b) RMSD Alignment hinge region averages visualized as bar graph.

3.6.3 RMSD flap region model analysis:
(a)

(b)

Figure 17. RMSD Model Alignment Flap Region. a) RMSD flap region
alignments at 5 ns intervals visualized by line graph (RMSD compared to WT vs
Time). b) RMSD Alignment flap region averages visualized as bar graph.
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CHAPTER IV: CONCLUSION AND DISCUSSIONS
4.1 Overview
HIV is an incurable virus that accounts for many deaths in the US and worldwide as documented
by the CDC (https://www.cdc.gov/hiv/basics/statistics.html). HIV often progresses to AIDS [6],
which ultimately decreases lifespan via modes such as opportunistic infections [2]. HIV protease
plays a crucial part in the viral life cycle [5, 6, 9-11] and without its ability to function the virus
is incapable of completing replication [1, 33]. Though protease inhibitors have been effective in
treating HIV infections [7, 9, 18, 34], HIV-1 PR has mutated as a potential means of preserving
its viral life cycle [14]. Multidrug resistant HIV is caused by specific mutations [11, 35].
Additionally, strains of multidrug resistant HIV-1 are more difficult to treat [11, 14-19]
potentially due to different intermolecular forces created by the changes in 6 key amino acids
[36]. It has been suggested that insertions may compensate for resistance mutations, but little
literature currently exists [14].
4.2 Key Findings
The insertion found in our clinical isolate created a shift in the protease structure, due to the
addition of an alpha helix to the hinge region. This altered hinge region appears to act as a
compensatory mechanism, reestablishing structural similarities to WT, which are necessary for
efficient cleavage of viral polyproteins [13, 14]. The structural change is a likely contributor to
the proteases ability to adopt “open” and “closed” conformations, as the hinge region is
implicated in making conformational changes [18] by controlling the movement of the flap
regions [10]. The flap residues are responsible for accessibility to the active site and subsequent
substrate recognition and cleavage [33]. The change in hinge structure and dynamics resulted in
a change in flap dynamics. The similarity in RMSD flap values for WT and MDR28 serves as
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evidence of compensation and structural restoration. The insertion itself may be, in part, due to
polymerase slippage [34] creating the consequential five amino acid repeat seen within the
isolate. However, it is reasonable to think that the MDR28 hinge alteration is a viral adaptation
as a means of promoting structural restoration, replicative capacity, and consequential viral
fitness.
4.3 Concluding Remarks
Further studies will need to be conducted to decisively conclude the role of insertions in viral
fitness.
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Abstract
Human immunodeficiency virus-1 (HIV-1) is a widespread, incurable retrovirus known to cause
immunodeficiency and a shortened life span. Despite successful treatment methods, HIV-1
frequently mutates, resulting in antiviral resistance. Many therapies target the HIV-1 protease
(PR), which is responsible for cleaving the viral polyprotein essential for its life cycle. HIV-1 PR
often evades treatment by way of mutations and less commonly through residue insertions. We
have identified a clinical isolate with a five residue insertion between residues 28 and 29.
Through molecular dynamics simulations we analyzed the protease protein structure and
determined that the residue insertion created a change in the secondary structure of the hinge
region of the viral protease. Elucidating the role of insertions could both aid in understanding
viral mutations as well as the theoretical effect on patient treatment/outcome.
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Section 2: Chikungunya nsP2 Protein Optimization, Purification, Expression and Drug
Design
CHAPTER I: INTRODUCTION
1.1 Chikungunya Virus Background:
Chikungunya virus (CHIKV) is a +ssRNA arbovirus belonging to the Alphavius genus, and the
Togavirdae family [35-50]. Chikungunya is considered a neglected tropical disease by the World
Health Association (WHO, http://www.who.int/neglected_diseases/diseases/en/), but is becoming
a growing concern as an emergent virus to non-tropical climates, resulting from climate change
and its consequential global warming, creating an increase in temperatures around the world [5056]. As an emerging virus, CHIKV may be most notable for severe arthralgia in infected patients
spanning from days to years [35-39, 41, 44, 45, 47, 49, 50, 57]. The pain is notoriously agonizing.
The name “Chikungunya” is derived from the Makonde language meaning, “that which bends up”
which serves as a descriptor of the contorted stance those plagued by severe arthralgia secondary
to CHIKV infection exemplify [49, 55, 56, 58]. CHIKV was first identified in East Africa during
the 1950s Tanzania outbreak [35, 37, 46, 49, 55, 59], but now affects a minimum of 45 countries
spanning the Caribbean, and the Americas [39, 40, 51, 54, 55, 57, 58, 60]. The ability for CHIKV
to span many countries is partially due to its mosquito vector. Its spread is additionally due to its
capacity to mutate as an RNA virus [35, 40, 49, 59-62]. Originally, vectored by the mosquito Aedes
aegypti, a mutation created the ability for a second, more aggressive mosquito Aedes albopictus to
vector and spread the virus [35, 37, 39, 40, 45-47, 49, 52-56, 58, 60-63, 64]. As the climate
continues to change, and mutations continue to occur, CHIKV will likely have the capability to
continually adapt and spread to new locations. Subsequently, a good understanding of the virus
and the viral life cycle is imperative. Furthermore, no FDA drugs are currently approved for the
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treatment of CHIKV which garners a need for development of drug therapies and vaccines to
prevent the spread of the disease to previously unaffected areas.
1.1.1 Cause:
CHIKV is caused by a mosquito vectored +ssRNA arbovirus [38, 41, 49, 50, 55, 56, 64]. It is a
zoonotic virus, passed between humans and non-human primates via mosquito bite [39, 40, 45,
46]. As an RNA virus CHIKV does not have proof-reading capabilities, making it adaptable by
way of mutations [62]. Because of its small genome, one point mutation can make a substantial
difference in transmission/vector compatibility [35, 40, 49, 59-62].

1.1.2 Viral Mechanism/Protease Significance:
The CHIKV genome is comprised of two open reading frames—one responsible for encoding
the nonstructural protein precursor polyprotein, and the second for the encoding of the precursor
polyprotein responsible for the three structural proteins [39, 45, 50]. There are four nonstructural
proteins: nsp1, nsp2, nsp3, and nsp4 [39, 41, 45, 48]. Structural proteins are responsible for
CHIKV viral enzymatic activities. The structural proteins are C (capsid), E1, and E2 (envelope
proteins) [39, 41, 45, 48]. These are responsible for non-enzymatic, protective components of the
virus. The nonstructural polyprotein is P1234, which is self-cleaved by the protease activity of
nsP2 [41, 44-46, 48-50]. The nonstructural proteins, after cleavage, form a replication complex
responsible for viral replication [41, 44-46, 48-50, 63]. Each nonstructural protein plays an
important role. Nsp1 plays a functional role in attaching the replication complex to the cell
membrane, thus acting as an anchor for the complex [41, 45]. Nsp2 has dual roles—cleaving
imperative viral nonstructural proteins of the replication complex with its protease and helicase
activity. Additionally, the nsp2 plays an active role in evading the host innate immune system by
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means of activating the transcription-coupled repair mechanism in the host cell. This repair
mechanism destroys polymerase II catalytic subunit, Rbp1, by ubiquitination and degradation.
This mechanism also suppresses JAK-STAT signaling pathway in the host cell —both of which
are necessary for viral propagation and survival in the host. Additionally, nsp2 has nucleoside
triphosphatase (NTPase) and RNA-dependent 5-triphosphatase capabilities [41, 44-49, 63]. Nsp3
functions as cofactor for nsp4 [41] and also acts as part of the replication complex. Aside from
its involvement as a cofactor, the function of nsp3 is not fully understood [45]. Lastly, nsp4 is the
RNA-dependent RNA polymerase responsible for replication [41, 45, 49]. Because of its
essential role in both evasion of the immune system and viral life cycle, nsp2 has been
recognized as a promising pharmaceutical target [44-48, 63].

1.2 Clinical Background
1.2.1 Impact/Demographic:
CHIKV was initially isolated in the early 1950s in Tanzania and northern Mozambique [35, 37,
46, 49, 55, 59]. At first it was thought to be a self-limiting tropical virus; however, it has been
reported to result in severe complications and fatalities [60, 61]. Throughout the last several
decades, CHIKV has continued to spread to new, unaffected regions and is now found in at least
45 countries [39, 40, 51, 57, 58, 60]. Presently, outbreaks cease to be contained to tropical
climates. The ability to infect other climates may increase due in part to mutations and infected
travelers, as well as climate change potentially influencing the vectors [37, 47, 50, 53, 55].

26

1.2.2 Symptoms:
CHIKV is characteristically known for the symptom of extreme arthralgia, which can be either
acute or chronic [35-39, 41, 44, 45, 47, 49-51, 53, 56, 57, 65]. The name of the CHIKV came
from the notorious, severe arthralgia it is known for. Its name means “that which bends up,”
which describes the contorted posture of an infected patient [49, 55, 56, 58]. The joint pain can
be debilitating and has the ability to progress into deforming arthritis [66]. Additionally, chronic
arthralgia can occur which can span for over a year post infection [57]. Chronic patients may
exhibit high levels of interleukin 6, as well as high levels of granulocyte macrophage colonystimulating factor without the normal increase in TNF or IL-1b characteristic of other forms of
inflammation triggered arthritis [61]. With the ongoing threat of spread due to increases in
globalized travel, global warming, and viral mutations facilitating adaption to new vectors [37,
47, 50, 53, 55], rheumatologists are likely to face challenging and unexpected cases of arthralgia
due to CHIKV as the virus migrates to more temperate, northern climates.
Normally symptoms are acute in nature, lasting from 3-10 days [50, 57]. Other symptoms
associated with CHIKV include an acute onset of high fever, nausea, vomiting, maculopapular
rash, myalgia, headache, and chills [35, 36, 39, 41, 44-47, 50, 53-56, 58, 64]. CHIKV patients
presenting with Guillain-Barre syndrome and associated neurological symptoms have been
reported [67]. Guillain-Barre syndrome is a rare condition, which can progress to troubling
symptoms such as flaccid quadriparesis and decreased swallowing and/or breathing capability
[67]. Although these symptoms are normally reversible, fatalities can occur due to
complications. Initially CHIKV was thought to be a self-limiting illness [39, 51, 53, 61],
however, its spread in Reunion Island resulted in 254 reported deaths related either directly or
indirectly to CHIKV [61]. With the potential emergence of CHIKV to previously unaffected
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areas it is important that medical professionals are prepared to diagnose and treat the condition
efficiently. Quick treatment may decrease the likelihood of chronic and debilitating symptoms
such as neurological complications, or even death.

1.2.3 Treatment/Prognosis:
No known FDA approved antivirals currently exist [68], although, a recent study conducted a
drug screen with potential for berberine, abamectin, and ivermectin (used as anti-insect or antiparasitic agents, with the potential for wide-spectrum antiviral use). These three agents showed a
reduction in viral RNA synthesis, although the mechanism of action is not fully understood [38].
Currently, treatments are focused on alleviating symptoms and inflammation.

1.3 Global Warming and Drug Design Urgency
1.3.1 Global Warming Predictions:
Over the past several decades, atmospheric changes have resulted from an increase in
greenhouse gases. Gasses indicated in the atmospheric changes include carbon dioxide, methane,
and nitrous oxide [69]. The increase of gasses due to manmade activity, such as fossil fuel
combustion, has led to a warming of the earth’s surface. [69, 70]. This increase in temperature
may facilitate an increase in diseases [69-71]. Viruses vectored by mosquitos, such as CHIKV,
present a threat of emergence with climate change as their vectors have the potential to carry out
their life cycle in new areas, due to the increased heat, moisture, deforestation, and other
ecological changes [55, 69-71]. CHIKV presents a substantial threat of complications to northern
climates with naïve populations, who are largely unexposed to the virus [64]. Unaffected
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populations have the potential to quickly spread the virus, suffer severe complications, and even
potential fatalities, due to exposure [60].

1.3.2 Vectors and Distribution:
CHIKV is primarily vectored by the Aedes aegypti and Aedes albopictus mosquitos [52-56, 58,
60, 61, 64]. CHIKV underwent a mutation first discovered in the 2006 La Reunion viral
outbreak, which created the ability for Aedes albopictus to act as a vector [60, 61]. Aedes
albopictus is capable of spreading the virus to a larger geographical range, due to its ability to
survive variable conditions—both rural and urban [52, 55 , 56, 58, 60, 61, 64]. Climate
predictions yielded varying results on the outcome for CHIKV vectors due to climate change
[72-83]. Although vector predictions vary, it is essential to be prepared as climate change
escalates. Furthermore, it is imperative that effective antiviral therapy is available to combat the
potential emergence of CHIKV and other vectored viruses in new geographic locations with
unaffected, at-risk populations.

1.4 Specific Aims:
The goal of this research is to optimize, express, and purify CHIKV nsP2 protease, with the
future direction of small molecule drug design to inhibit nsP2.

1.5 Significance:
Currently there are no known FDA approved CHIKV treatments. CHIKV outbreak is treated by
alleviating symptoms, as no known, effective antiviral exists. With the threat of Arboviral
emergence to unaffected areas of the world, pharmaceutical treatments are imperative.
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CHAPTER II: MATERIALS AND METHODS
2.1 Cloning and Small Scale Expression:
Chikungunya virus nsp2 protease (CHIKV) was cloned into a SUMO vector at EZbiolab, inc.
(EZBioLab, 2015). A fusion protein was made with a 6x His attached to a SUMO tag, followed
by the nsp2 CHIKV sequence with an Ampicillin resistance gene. The clone was transformed
into Escherichia coli BL21 Codon Plus (DE3) cells for protein expression.
Protein expression optimization was preformed using 5 mL, small scale cultures. The SUMO
tagged CHIKV protein was grown in 5 mL LB medium in the presence of Ampicillin. Protein
expression was induced by addition of isopropyl-β-D-thiogalactoside (IPTG). To optimize
protein overexpression the following variables were tested: optical density(OD600) prior to
induction, IPTG concentration, and temperature. Induction of the cell cultures was carried out at
OD600 0.5 or 1.0 with the addition of IPTG at the following concentrations: 0.1mM, 0.5mM, or
1.0mM. Following IPTG induction of the cell culture, protein expression was carried out at
either 37°C for three hours or 15°C overnight. After the incubation period the cells were lysed
using lysozyme and polyacrylamide gel electrophoresis(SDS-PAGE) (15% w/v polyacrylamide)
was used to determine protein expression levels and solubility (Figure 18). Results of
optimization summarized in Figure 19.
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Figure 18. Nsp2 Optimization.
Protein optimization of CHIKV
nsp2. First gel (top) tested the
OD600 condition. Second set
of gels (middle) tested IPTG
concentration. The third set of
gels (bottom) tested
temperature. Constant
conditions are listed and
boxed to the left of the
corresponding SDS-PAGE gel.

Temp: 37 ⁰C
OD600: 1.0

Temp: 37 ⁰C
[IPTG]: 0.5mM

0.5 OD600

1.0 OD600

66.4 kDa
55.6 kDa
27.0 kDa

0.1 mM IPTG

1.0 mM IPTG

0.5 mM IPTG

66.4 kDa
55.6 kDa

27.0 kDa

[IPTG]

Temp.

0.1 mM

15°C

0.5

0.5 mM

37°C

1.0

OD

600

[IPTG]: 0.5mM
OD: 1.0

Temp: 15 ⁰C

Temp: 37 ⁰C

1.0 mM

Figure 19. Optimization Results. Summary
of optimization results for nsp2.
Optimization showed the best
temperature is 15°C, IPTG concentration
as 0.5mM, and the best OD600 as 1.0.

66.4 kDa
55.6 kDa

66.4 kDa
55.6 kDa

27.0 kDa

27.0 kDa

31

2.2 Large Scale Protein Expression and Purification:
Large scale protein expression was attained using 2 liter cultures. The optimized condition for
growth of the cultures was as follows: induction with 0.5mM concentration of IPTG, OD600 of
1.0, expression at 15°C overnight. The following day the cells were harvested via centrifugation
and lysed by French Press. A Ni2+ affinity column (HisTrap™ HP, GE) was used to purify the
soluble fraction. The SUMO tag was separated from CHIKV by proteolytic cleavage of the His6SUMO tag with yeast SUMO Protease 1 after the elution of the fractions. The cleaved protein
was subjected to an additional round of Ni2+ purification followed by size-exclusion
chromatography (Superdex 200, GE). Purified CHIKV was collected and concentrated to ~19
mg/mL. The accuracy of the purified protein in the elution fractions were tested using SDSPAGE (15% w/v polyacrylamide). The gels were used to analyze the filtrate based on size and
Coomassie Brilliant Blue staining was used to visualize the protein bands.

2.3 Characterization of Enzyme Activity
FRET-based fluorometric enzyme assay was used to test the enzymatic activity of CHIKV.
CHIKV was diluted in reaction buffer containing Tris 50mM, NaCl 10mM, at a pH of 9.1 to a
final concentration of 539 nM. The reaction was initiated by adding FRET substrate (AnaSpec
Inc.). The substrate used is based on the P4-P5’ residues of the nsp1/nsp2 (residues
RAGAGIEK), nsp2/nsp3 (RAGCAPSYK), and nsp3/nsp4 (RAGGYIFSK) cleavage sites. The
FRET substrate was serially diluted from concentrations of 100 µM to 39 nM and 75µM to
37.5µM then added to the reaction to determine the kinetic parameters. The final reaction
volume within the well was 100 µL. A microplate reader (SpectraMax M5, Molecular Devices,
Sunnyvale, CA, USA) was responsible for monitoring the fluorescence emitted by substrate

32

cleavage at 488 nm excitation wavelength with an emission wavelength of 520 nm. The reaction
was performed at 37°C with readings taken every minute for a total duration of 21 minutes.
Standard curves were created, data was plotted and analyzed using GraphPad Prism v. 6.07.

CHAPTER III: RESULTS

1.

Cell lysate
(soluble fraction)

3.

4.
Size Exclusion

Using the optimized overexpression conditions

2+

2+

Protease:

Ni Affinity

Ni Affinity

3.1 Overexpression and Purification of CHIKV

outlined in section 2.1, a 2 liter culture of E. coli
was used to overexpress CHIKV. The resulting

2.

ULP-1
cleavage

cells were collected via centrifugation and
lysed by French press, Figure 20 [1]shows a
flowchart representing the order in which
purification occurred. Expressed SUMO-

Figure 20. Protein Purification Scheme [1].
Purification was accomplished through two Ni2+
affinity columns (with ULP-1 cleavage of SUMO
between), and subsequent Size Exclusion
chromatography.

CHIKV fusion protein is seen at ~ 55.6 kDa
molecular weight on a 15% v/w polyacrylamide SDS-PAGE gel as shown in Figure 21. The first
Ni2+ column was applied with the elution of SUMO-CHIKV protein as a result of an imidazole
gradient. Figure 21 shows the results from the first Ni2+ column as well as the desalting column,
visualized on SDS-PAGE. The elution fractions B1-B6 were cleaved by yeast SUMO protease to
remove the SUMO tag from CHIKV prior to the second Ni 2+purification. CHIKV was eluted
from second a Ni2+ column as seen in Figure 22. Partial ULP cleavage was observed, and SDS-
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PAGE showed three protein bands.
CHIKV is expected to present with the
molecular weight of 37.4kDa, but bands

66.4 kDa
55.6 kDa
42.4 kDa
34.6 kDa

were displayed at the experimental

27.0 kDa

molecular weight of ~55.6kDa, ~35kDa,
and ~19kDa on SDS-PAGE gel as seen in
figure D. These results indicate partial
ULP-1 cleavage, resulting in fusion
protein, nsp2, and SUMO protein,
respectively.

66.4 kDa
55.6 kDa
42.4 kDa

A final round of purification was

34.6 kDa

obtained using size-exclusion

27.0 kDa

chromatography. A strong, symmetrical
peek is seen at ~86 mL indicting the
beginning of CHIKV elution. The
symmetrical peak indicates successful
protein purification representative of only
one species (Figure 23). Fractions D3D12 were concentrated to ~19mg/mL.

66.4 kDa
55.6 kDa
42.4 kDa
34.6 kDa
27.0 kDa

Figure 21. Optimization, First Nickel Column, and
Desalting Column. (Top) SDS-PAGE gel containing the
following: lane 1: marker; lane 2: induced; lane 3:
uninduced; lane 4: total, lane 5: supernatant; lane 6 & 7:
fractions after first Ni2+ column; Lanes 8 & 9: before/after
ULP cleavage; lane 10: desalt column. Protein is soluble,
but incomplete ULP cleavage is observed. (Bottom) SDSPAGE gel containing the following: lane 1: marker; lanes 27: 1st Ni2+ column elution fractions; lanes 8-10 blank.
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3.2 Characterization of
Enzyme Activity
FRET based assays were
used to test enzymatic
activity of purified CHIKV
as described in section 2.3.
Each substrate was tested to
determine enzyme activity in
the presence and absence of
DTT in relation to the
following cleavage sites
(residues P4-P5’): nsp1/nsp2,

66.4 kDa
55.6 kDa
42.4 kDa
34.6 kDa
27.0 kDa

nsp2/nsp3, and nsp3/nsp4.
Each peptide contained a
fluorescent tag (Hilyte Fluor
TM

, AnaSpec, Inc.) on the N-

terminus of the P4 Arginine.
The enzyme optimization data is
shown in Figure 24 as relative
fluorescent units (RFU) as a
function of enzyme

Figure 23. Size-exclusion Elution. Results for the size exclusion
elution. The sample shows a symmetric peak (top) when
measuring the absorbance vs mL of sample, and one protein band
(bottom) in SDS-PAGE gel, indicating successful purification of
CHIKV nsp2. The lanes of the SDS-PAGE are as follows: lane 1:
marker; lane 2: gel load; lanes 3-10: size-exclusion elution
fractions.
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concentration. The nsp1/nsp2
cleavage site showed the highest
RFU (~0.3 RFU) without DTT at
~256nM enzyme concentration.
The nsp2/nsp3 cleavage site
showed similar RFU values with
and without DTT. The highest
nsp2/nsp3 RFU (~0.25) was seen
with DTT at ~512nM enzyme
concentration. The nsp3/nsp4 did
not show activity.

CHAPTER IV:
CONCLUSIONS AND
DISCUSSIONS
4.1 Overview:
Expression, purification, and
characterization of CHIKV was
successful, yielding ~19 mg/mL or purified
protein. The kinetic assays confirmed
activity of CHIKV nsp2, further studies will

Figure 24. Enzyme Activity Assay. Enzyme
optimization assay results measured as a
function of RFU as a function of enzyme
concentration. Results recorded without
(top) and with (bottom) DTT.
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aim at elucidating accurate binding information, as well as small molecule drug design.

4.2 Key Findings:
CHIKV appears to have an affinity for the gels used in purification. It is possible that this is due
to ribose binding, as nsp2 is involved in the formation of the replication complex, and due to its
NTPase activity, which provides energy for its helicase activity [41]. Additionally, when
optimizing the protein, we found that it expresses best at lower temperatures (15 ⁰C). This may
be in part due to its association with the replication complex docked to the cytosolic cell
membrane [41]. The kinetic assays show enzymatic activity, creating the potential to test drug
targets with nsp2, active protease.

4.3 Concluding Remarks:
In summary, we successfully optimized, expressed, and purified CHIKV nsp2 and conducted
enzyme characterization assays which validated the enzymes activity. No FDA approved
treatments currently exist for CHIKV, but with the threat of an Arborviral migration to
previously unaffected climates due to global warming and other globalization factors, drug
design to inhibit fundamental portions of the viral cycle is imperative. Future studies will aim to
conduct drug screens and to crystalize wildtype CHIKV to yield accurate results for potential
small molecule protease inhibitors.
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Abstract:
Chikungunya virus (CHIKV) is an incurable Arbovirus creating the most notable symptom of
severe and sometimes chronic arthralgia. CHIKV is considered a neglected tropical virus by the
World Health Association (WHO), with the potential of becoming a larger scale threat in part
due to the influence of global warming on the mosquito population that serve as vectors for
CHIKV. The virus has a life cycle is dependent on its nonstructural protein function, one of
specific interest is nsP2. We have successfully expressed, optimized, and purified active CHIKV
nsP2. Future studies will look at small peptidomimetic drug design.

38

References
[1] Kuiper, B.D., Slater, K., Spellmon, N., Holcomb, J., Medapureddy, P., Muzzarelli, K.M., et al. Increased
activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. Biochem
Biophys Res Commun. 2017.
[2] Liu, Z., Huang, X., Hu, L., Pham, L., Poole, K.M., Tang, Y., et al. Effects of Hinge-region Natural
Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug
Pressure Evolution. J Biol Chem. 2016, 291, 22741-56.
[3] Chow, A., Tey, J., Win, M.K., Leo, Y.S. Causes of death and factors associated with early death among
human immunodeficiency virus (HIV)-infected persons in Singapore: pre-highly active antiretroviral
therapy (HAART) and Peri-HAART. Ann Acad Med Singapore. 2012, 41, 563-70.
[4] Bandaranayake, R.M., Kolli, M., King, N.M., Nalivaika, E.A., Heroux, A., Kakizawa, J., et al. The effect
of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
J Virol. 2010, 84, 9995-10003.
[5] Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B.K., Baldwin, E., Weber, I.T., et al.
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989,
245, 616-21.
[6] Liu, Z., Wang, Y., Brunzelle, J., Kovari, I.A., Kovari, L.C. Nine crystal structures determine the substrate
envelope of the MDR HIV-1 protease. Protein J. 2011, 30, 173-83.
[7] Sayer, J.M., Agniswamy, J., Weber, I.T., Louis, J.M. Autocatalytic maturation, physical/chemical
properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance. Protein Sci.
2010, 19, 2055-72.
[8] Bannwarth, L., Rose, T., Dufau, L., Vanderesse, R., Dumond, J., Jamart-Gregoire, B., et al. Dimer
disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wildtype and multidrug-resistant mutated HIV-1 proteases. Biochemistry. 2009, 48, 379-87.
[9] Meher, B.R., Wang, Y. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to
inhibitor TMC114: flap dynamics and binding mechanism. J Mol Graph Model. 2015, 56, 60-73.
[10] Yu, Y., Wang, J., Shao, Q., Shi, J., Zhu, W. Effects of drug-resistant mutations on the dynamic
properties of HIV-1 protease and inhibition by Amprenavir and Darunavir. Sci Rep. 2015, 5, 10517.
[11] Louis, J.M., Roche, J. Evolution under Drug Pressure Remodels the Folding Free-Energy Landscape of
Mature HIV-1 Protease. J Mol Biol. 2016, 428, 2780-92.
[12] Agniswamy, J., Shen, C.H., Aniana, A., Sayer, J.M., Louis, J.M., Weber, I.T. HIV-1 protease with 20
mutations exhibits extreme resistance to clinical inhibitors through coordinated structural
rearrangements. Biochemistry. 2012, 51, 2819-28.
[13] Andersson, H.O., Fridborg, K., Lowgren, S., Alterman, M., Muhlman, A., Bjorsne, M., et al.
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. Eur J Biochem.
2003, 270, 1746-58.
[14] Silva, A.M., Cachau, R.E., Sham, H.L., Erickson, J.W. Inhibition and catalytic mechanism of HIV-1
aspartic protease. J Mol Biol. 1996, 255, 321-46.
[15] Cai, Y., Myint, W., Paulsen, J.L., Schiffer, C.A., Ishima, R., Kurt Yilmaz, N. Drug Resistance Mutations
Alter Dynamics of Inhibitor-Bound HIV-1 Protease. J Chem Theory Comput. 2014, 10, 3438-48.
[16] Nair, A.C., Miertus, S., Tossi, A., Romeo, D. A computational study of the resistance of HIV-1 aspartic
protease to the inhibitors ABT-538 and VX-478 and design of new analogues. Biochem Biophys Res
Commun. 1998, 242, 545-51.

39
[17] Kim, E.Y., Winters, M.A., Kagan, R.M., Merigan, T.C. Functional correlates of insertion mutations in
the protease gene of human immunodeficiency virus type 1 isolates from patients. J Virol. 2001, 75,
11227-33.
[18] Ding, F., Layten, M., Simmerling, C. Solution structure of HIV-1 protease flaps probed by comparison
of molecular dynamics simulation ensembles and EPR experiments. J Am Chem Soc. 2008, 130, 7184-5.
[19] Nakashima, M., Ode, H., Suzuki, K., Fujino, M., Maejima, M., Kimura, Y., et al. Unique Flap
Conformation in an HIV-1 Protease with High-Level Darunavir Resistance. Front Microbiol. 2016, 7, 61.
[20] Appadurai, R., Senapati, S. Dynamical Network of HIV-1 Protease Mutants Reveals the Mechanism
of Drug Resistance and Unhindered Activity. Biochemistry. 2016, 55, 1529-40.
[21] Petropoulos, C.J., Parkin, N.T., Limoli, K.L., Lie, Y.S., Wrin, T., Huang, W., et al. A novel phenotypic
drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother.
2000, 44, 920-8.
[22] Cunningham, S., Ank, B., Lewis, D., Lu, W., Wantman, M., Dileanis, J.A., et al. Performance of the
applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for
sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001, 39, 1254-7.
[23] Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., et al. SWISS-MODEL:
modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res.
2014, 42, W252-8.
[24] Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L., Schwede, T. The SWISS-MODEL Repository and
associated resources. Nucleic Acids Res. 2009, 37, D387-92.
[25] Arnold, K., Bordoli, L., Kopp, J., Schwede, T. The SWISS-MODEL workspace: a web-based
environment for protein structure homology modelling. Bioinformatics. 2006, 22, 195-201.
[26] Guex, N., Peitsch, M.C., Schwede, T. Automated comparative protein structure modeling with
SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis. 2009, 30 Suppl 1, S16273.
[27] Muzammil, S., Armstrong, A.A., Kang, L.W., Jakalian, A., Bonneau, P.R., Schmelmer, V., et al. Unique
thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug
resistance mutations. J Virol. 2007, 81, 5144-54.
[28] Humphrey, W., Dalke, A., Schulten, K. VMD: visual molecular dynamics. J Mol Graph. 1996, 14, 33-8,
27-8.
[29] Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., et al. Scalable molecular
dynamics with NAMD. J Comput Chem. 2005, 26, 1781-802.
[30] Best, R.B., Zhu, X., Shim, J., Lopes, P.E., Mittal, J., Feig, M., et al. Optimization of the additive
CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and sidechain chi(1) and chi(2) dihedral angles. J Chem Theory Comput. 2012, 8, 3257-73.
[31] Dewdney, T.G., Wang, Y., Kovari, I.A., Reiter, S.J., Kovari, L.C. Reduced HIV-1 integrase flexibility as a
mechanism for raltegravir resistance. J Struct Biol. 2013, 184, 245-50.
[32] Salisburg, A.M., Deline, A.L., Lexa, K.W., Shields, G.C., Kirschner, K.N. Ramachandran-type plots for
glycosidic linkages: Examples from molecular dynamic simulations using the Glycam06 force field. J
Comput Chem. 2009, 30, 910-21.
[33] Soares, R.O., Torres, P.H., da Silva, M.L., Pascutti, P.G. Unraveling HIV protease flaps dynamics by
Constant pH Molecular Dynamics simulations. J Struct Biol. 2016, 195, 216-26.
[34] Jordan, P.S., Poon, A., Eron, J., Squires, K., Ignacio, C., Richman, D.D., et al. A novel codon insert in
protease of clade B HIV type 1. AIDS Res Hum Retroviruses. 2009, 25, 547-50.
[35] Carrera, J.P., Diaz, Y., Denis, B., Barahona de Mosca, I., Rodriguez, D., Cedeno, I., et al. Unusual
pattern of chikungunya virus epidemic in the Americas, the Panamanian experience. PLoS Negl Trop Dis.
2017, 11, e0005338.

40
[36] Pastula, D.M., Hancock, W.T., Bel, M., Biggs, H., Marfel, M., Lanciotti, R., et al. Chikungunya virus
disease outbreak in Yap State, Federated States of Micronesia. PLoS Negl Trop Dis. 2017, 11, e0005410.
[37] Tsetsarkin, K.A., Chen, R., Weaver, S.C. Interspecies transmission and chikungunya virus emergence.
Curr Opin Virol. 2016, 16, 143-50.
[38] Varghese, F.S., Kaukinen, P., Glasker, S., Bespalov, M., Hanski, L., Wennerberg, K., et al. Discovery of
berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral
Res. 2016, 126, 117-24.
[39] Agarwal, A., Dash, P.K., Singh, A.K., Sharma, S., Gopalan, N., Rao, P.V., et al. Evidence of
experimental vertical transmission of emerging novel ECSA genotype of Chikungunya Virus in Aedes
aegypti. PLoS Negl Trop Dis. 2014, 8, e2990.
[40] Tsetsarkin, K.A., Weaver, S.C. Sequential adaptive mutations enhance efficient vector switching by
Chikungunya virus and its epidemic emergence. PLoS Pathog. 2011, 7, e1002412.
[41] Bourai, M., Lucas-Hourani, M., Gad, H.H., Drosten, C., Jacob, Y., Tafforeau, L., et al. Mapping of
Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component.
J Virol. 2012, 86, 3121-34.
[42] Leung, J.Y., Ng, M.M., Chu, J.J. Replication of alphaviruses: a review on the entry process of
alphaviruses into cells. Adv Virol. 2011, 2011, 249640.
[43] Thomas, S., Rai, J., John, L., Schaefer, S., Putzer, B.M., Herchenroder, O. Chikungunya virus capsid
protein contains nuclear import and export signals. Virol J. 2013, 10, 269.
[44] Ramakrishnan, C., Kutumbarao, N.H., Suhitha, S., Velmurugan, D. Structure-function relationship of
Chikungunya nsP2 protease: A comparative study with papain. Chem Biol Drug Des. 2016.
[45] Fros, J.J., Pijlman, G.P. Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses.
Viruses. 2016, 8.
[46] Saisawang, C., Sillapee, P., Sinsirimongkol, K., Ubol, S., Smith, D.R., Ketterman, A.J. Full length and
protease domain activity of chikungunya virus nsP2 differ from other alphavirus nsP2 proteases in
recognition of small peptide substrates. Biosci Rep. 2015, 35.
[47] Bao, H., Ramanathan, A.A., Kawalakar, O., Sundaram, S.G., Tingey, C., Bian, C.B., et al. Nonstructural
protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV
envelope protein expressing DNA Vaccine. Viral Immunol. 2013, 26, 75-83.
[48] Akhrymuk, I., Kulemzin, S.V., Frolova, E.I. Evasion of the innate immune response: the Old World
alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J
Virol. 2012, 86, 7180-91.
[49] Fros, J.J., Liu, W.J., Prow, N.A., Geertsema, C., Ligtenberg, M., Vanlandingham, D.L., et al.
Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J
Virol. 2010, 84, 10877-87.
[50] Pohjala, L., Utt, A., Varjak, M., Lulla, A., Merits, A., Ahola, T., et al. Inhibitors of alphavirus entry and
replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One.
2011, 6, e28923.
[51] Pineda, C., Munoz-Louis, R., Caballero-Uribe, C.V., Viasus, D. Chikungunya in the region of the
Americas. A challenge for rheumatologists and health care systems. Clin Rheumatol. 2016, 35, 2381-5.
[52] Roiz, D., Bousses, P., Simard, F., Paupy, C., Fontenille, D. Autochthonous Chikungunya Transmission
and Extreme Climate Events in Southern France. PLoS Negl Trop Dis. 2015, 9, e0003854.
[53] Yactayo, S., Staples, J.E., Millot, V., Cibrelus, L., Ramon-Pardo, P. Epidemiology of Chikungunya in
the Americas. J Infect Dis. 2016, 214, S441-S5.
[54] Kuri-Morales, P.A., Guzman-Morales, E., De La Paz-Nicolau, E., Salas-Fernandez, A. [Emerging and
reemerging diseases]. Gac Med Mex. 2015, 151, 674-80.

41
[55] Waldock, J., Chandra, N.L., Lelieveld, J., Proestos, Y., Michael, E., Christophides, G., et al. The role of
environmental variables on Aedes albopictus biology and chikungunya epidemiology. Pathog Glob
Health. 2013, 107, 224-41.
[56] Weber, C., Konig, R., Niedrig, M., Emmerich, P., Schnierle, B.S. A neutralization assay for
chikungunya virus infections in a multiplex format. J Virol Methods. 2014, 201, 7-12.
[57] Feldstein, L.R., Rowhani-Rahbar, A., Staples, J.E., Weaver, M.R., Halloran, M.E., Ellis, E.M. Persistent
Arthralgia Associated with Chikungunya Virus Outbreak, US Virgin Islands, December 2014-February
2016. Emerg Infect Dis. 2017, 23, 673-6.
[58] Gutierrez-Saravia, E., Gutierrez, C.E. Chikungunya Virus in the Caribbean: A Threat for All of the
Americas. J Pediatric Infect Dis Soc. 2015, 4, 1-3.
[59] Christofferson, R.C., Chisenhall, D.M., Wearing, H.J., Mores, C.N. Chikungunya viral fitness measures
within the vector and subsequent transmission potential. PLoS One. 2014, 9, e110538.
[60] Chikungunya disease: gaps and opportunities in public health and research in the Americas. Wkly
Epidemiol Rec. 2015, 90, 571-6.
[61] Madariaga, M., Ticona, E., Resurrecion, C. Chikungunya: bending over the Americas and the rest of
the world. Braz J Infect Dis. 2016, 20, 91-8.
[62] Arias-Goeta, C., Moutailler, S., Mousson, L., Zouache, K., Thiberge, J.M., Caro, V., et al. Chikungunya
virus adaptation to a mosquito vector correlates with only few point mutations in the viral envelope
glycoprotein. Infect Genet Evol. 2014, 24, 116-26.
[63] Mathur, K., Anand, A., Dubey, S.K., Sanan-Mishra, N., Bhatnagar, R.K., Sunil, S. Analysis of
chikungunya virus proteins reveals that non-structural proteins nsP2 and nsP3 exhibit RNA interference
(RNAi) suppressor activity. Sci Rep. 2016, 6, 38065.
[64] Diaz-Gonzalez, E.E., Kautz, T.F., Dorantes-Delgado, A., Malo-Garcia, I.R., Laguna-Aguilar, M.,
Langsjoen, R.M., et al. First Report of Aedes aegypti Transmission of Chikungunya Virus in the Americas.
Am J Trop Med Hyg. 2015, 93, 1325-9.
[65] Scully, C., Samaranayake, L.P. Emerging and changing viral diseases in the new millennium. Oral Dis.
2016, 22, 171-9.
[66] Vijayan, V., Sukumaran, S. Chikungunya Virus Disease: An Emerging Challenge for the
Rheumatologist. J Clin Rheumatol. 2016, 22, 203-11.
[67] Agarwal, A., Vibha, D., Srivastava, A.K., Shukla, G., Prasad, K. Guillain-Barre syndrome complicating
chikungunya virus infection. J Neurovirol. 2017.
[68] Nawas, Z.Y., Tong, Y., Kollipara, R., Peranteau, A.J., Woc-Colburn, L., Yan, A.C., et al. Emerging
infectious diseases with cutaneous manifestations: Viral and bacterial infections. J Am Acad Dermatol.
2016, 75, 1-16.
[69] Rossati, A. Global Warming and Its Health Impact. Int J Occup Environ Med. 2017, 8, 7-20.
[70] Barrett, B., Charles, J.W., Temte, J.L. Climate change, human health, and epidemiological transition.
Prev Med. 2015, 70, 69-75.
[71] Shope, R. Global climate change and infectious diseases. Environ Health Perspect. 1991, 96, 171-4.
[72] Escobar, L.E., Romero-Alvarez, D., Leon, R., Lepe-Lopez, M.A., Craft, M.E., Borbor-Cordova, M.J., et
al. Declining Prevalence of Disease Vectors Under Climate Change. Sci Rep. 2016, 6, 39150.
[73] Cunze, S., Kochmann, J., Koch, L.K., Klimpel, S. Aedes albopictus and Its Environmental Limits in
Europe. PLoS One. 2016, 11, e0162116.
[74] Equihua, M., Ibanez-Bernal, S., Benitez, G., Estrada-Contreras, I., Sandoval-Ruiz, C.A., MendozaPalmero, F.S. Establishment of Aedes aegypti (L.) in mountainous regions in Mexico: Increasing number
of population at risk of mosquito-borne disease and future climate conditions. Acta Trop. 2017, 166,
316-27.
[75] Lima-Camara, T.N. Emerging arboviruses and public health challenges in Brazil. Rev Saude Publica.
2016, 50.

42
[76] Koch, L.K., Cunze, S., Werblow, A., Kochmann, J., Dorge, D.D., Mehlhorn, H., et al. Modeling the
habitat suitability for the arbovirus vector Aedes albopictus (Diptera: Culicidae) in Germany. Parasitol
Res. 2016, 115, 957-64.
[77] Ogden, N.H., Milka, R., Caminade, C., Gachon, P. Recent and projected future climatic suitability of
North America for the Asian tiger mosquito Aedes albopictus. Parasit Vectors. 2014, 7, 532.
[78] Rochlin, I., Ninivaggi, D.V., Hutchinson, M.L., Farajollahi, A. Climate change and range expansion of
the Asian tiger mosquito (Aedes albopictus) in Northeastern USA: implications for public health
practitioners. PLoS One. 2013, 8, e60874.
[79] Smith, C.D., Freed, T.Z., Leisnham, P.T. Prior Hydrologic Disturbance Affects Competition between
Aedes Mosquitoes via Changes in Leaf Litter. PLoS One. 2015, 10, e0128956.
[80] Alto, B.W., Juliano, S.A. Precipitation and temperature effects on populations of Aedes albopictus
(Diptera: Culicidae): implications for range expansion. J Med Entomol. 2001, 38, 646-56.
[81] Adelman, Z.N., Anderson, M.A., Wiley, M.R., Murreddu, M.G., Samuel, G.H., Morazzani, E.M., et al.
Cooler temperatures destabilize RNA interference and increase susceptibility of disease vector
mosquitoes to viral infection. PLoS Negl Trop Dis. 2013, 7, e2239.
[82] Thongsripong, P., Green, A., Kittayapong, P., Kapan, D., Wilcox, B., Bennett, S. Mosquito vector
diversity across habitats in central Thailand endemic for dengue and other arthropod-borne diseases.
PLoS Negl Trop Dis. 2013, 7, e2507.
[83] Samy, A.M., Elaagip, A.H., Kenawy, M.A., Ayres, C.F., Peterson, A.T., Soliman, D.E. Climate Change
Influences on the Global Potential Distribution of the Mosquito Culex quinquefasciatus, Vector of West
Nile Virus and Lymphatic Filariasis. PLoS One. 2016, 11, e0163863.

